Such heterogeneity in survival may mirror the differences in tumor growth kinetics between IDH1 mutant and wild-type gliomas, with wild-type gliomas showing a faster rate cell proliferation than the mutant ones.11 Differences in HGG proliferation may also play a substantial role in the heterogeneity of patients’ symptoms at admission. This evidence concerns the gene IDH1 and neoplasm.